A long-term maintenance study suggested continuing mirikizumab for 104 weeks is safe and provides durable benefit in patients with active ulcerative colitis.

Related Keywords

New York , United States , Brucee Sands , , Icahn School Of Medicine , Inflammatory Bowel Disease Questionnaire , Icahn School , Mount Sinai , New York City , Inflammatory Bowel ,